Citron

Citron Research's latest target is AveXis Inc (NASDAQ: AVXS), a clinical-stage gene therapy company that focuses on creating gene therapy treatments for patients suffering from neurological genetic diseases. Citron Research, the notable short-selling research firm, blasted AveXis in a report dated...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s 50 percent plunge on Tuesday is also sparking a selloff in another drug company that Citron's Andrew Left says is the “poster child” for price gouging: Mallinckrodt PLC (NYSE: MNK). Mallinckrodt owns two different drugs, Acthar...

Shares of Internet services firm J2 Global Inc (NASDAQ: JCOM) recovered after a heavy selloff on Thursday, which saw its stock price plunge as much as 20 percent following a Citron sell report. J2 Global responded to the report saying, "We believe it is both factually incorrect and wrongly...

Shares of Fitbit Inc (NYSE: FIT) hit a day's high of $14.52 after short-seller Andrew Left's positive comments on the company. "Tough to short here because wearables are for real with a big total addressable market. It is a compelling product," Citron Research's Andrew...

Tesla Motors Inc (NASDAQ: TSLA) shares have had quite a week. While the issue is up 13.25 percent over the past five trading days, Tuesday afternoon and Wednesday saw some significant action following a tweet by Andrew Left of Citron. Left's Tuesday tweet supported shorting Tesla for multiple...

Tesla Motors Inc (NASDAQ: TSLA) shares are recovering on Wednesday after Citron's Andrew Left tweeted on Tuesday that he's again short the stock with a price target of $100. "Recently, as the price of oil started to increase in the past week as did the price of Tesla...I heard too...

Valeant Pharmaceuticals Intl Inc. (NYSE: VRX) shares plunged nearly 9 percent in Monday's after-hours trading session following word the company may have to restate financial results, before recovering slightly. The potential restatement, according to sources, would come on the heels of a...

In an emphatic report Friday, Citron Research boasts on Monster Beverage Corporation (NASDAQ: MNST), "MNST has continued to defy gravity— as if the stock drank four cans of its own product." Among Monster's achievements, Citron highlighted its pricing power: "The bear...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares are relatively unchanged in Tuesday's after-hours session following a press release from Philidor. The specialty pharma company said it's "deeply disappointed" its working relationship with Valeant has ended, adding that it...

Pharma giant Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is crashing on Wednesday after a scathing new report from Citron Research. Shares have fallen as low as $101, a 31 percent decline. The stock opened the day's trading near $150 per share -- an enormous move for a company with a...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were trading lower by more than 3 percent Friday morning. Shares of Valeant have come under pressure over concerns of price gouging and a plea for a subpoena by Bernie Sanders to see all communication regarding price hikes. Citron Research...

Citron Research released a new report on Ambarella Inc (NASDAQ: AMBA) that reiterated the firm’s extremely bearish outlook for the chip maker. In the report, Citron specifically calls out Jim Cramer’s bullish thesis for Ambarella as “ridiculousness,” and then explains how...